title: Morphological and immunohistochemical study of ovarian and tubal dysplasia associated with tamoxifen.
abstract: Ovarian epithelial dysplasia was initially described in material from prophylactic oophorectomies for BReast CAncer gene (BRCA) mutation. Similar histopathological abnormalities have been revealed after ovulation stimulation. Given that tamoxifen (TAM) has a clomid-like effect and is sometimes used to induce ovulation, we studied the morphological features and immunohistochemical expression patterns of neoplasia-associated markers in adnexectomies previously exposed to TAM for breast cancer. We blindly reviewed 173 histopathological slides of adnexectomies according to three groups - oophorectomie sassociated with TAM exposure (n=42), oophorectomies associated with clomiphene exposure (n=15) and a spontaneously fertile non cancerous control group (n=116). Morphological features (with an ovarian and tubal dysplasia scoring system) and immunohistochemical expression patterns of Ki-67, p53 and Aldehyde dehydrogenase 1 (ALDH1 is an enzyme significantly associated with earlystage ovarian cancer) were evaluated and correlated. Mean tubal dysplasia score was significantly higher in the TAM group and clomiphene group than in controls (respectively 7.8 vs 3.5, P&lt;0.007 and 6.8 vs 3.5, P=0.008). There is no statistical difference for the ovarian score in TAM group in comparison with the control group whereas we found a significant score for clomiphen group (6.5, P=0.009). Increased ALDH1 expression was observed in the two exposed group whereas expression patterns of Ki67 and p53 were moderate. Interestingly, ALDH1 expression was low in non-dysplastic epithelium, high in dysplasia, and constantly low in the two carcinoma. Furthermore, we confirm our previous results showing that ALDH1 may be a useful tissue biomarker in the subtle histopathological diagnosis of tubo-ovarian dysplasia.
authors.affiliation: Centre Jean Perrin, ERTICA Research Team. chenegautier@yahoo.fr.
authors.forename: G
authors.initials: G
authors.lastname: Chene
authors.forename: N
authors.initials: N
authors.lastname: Radosevic-Robin
authors.forename: A S
authors.initials: AS
authors.lastname: Tardieu
authors.forename: A
authors.initials: A
authors.lastname: Cayre
authors.forename: I
authors.initials: I
authors.lastname: Raoelfils
authors.forename: P
authors.initials: P
authors.lastname: Dechelotte
authors.forename: J
authors.initials: J
authors.lastname: Dauplat
authors.forename: F
authors.initials: F
authors.lastname: Penault Llorca
mesh_terms: D000080924:Aldehyde Dehydrogenase 1 Family; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D005185:Fallopian Tube Neoplasms / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D019394:Ki-67 Antigen / Q000378:metabolism; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D010051:Ovarian Neoplasms / Q000737:chemistry / Q000378:metabolism / Q000473:pathology; D011230:Precancerous Conditions / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D050697:Retinal Dehydrogenase / Q000378:metabolism; D012189:Retrospective Studies; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007527:Isoenzymes; D019394:Ki-67 Antigen; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D013629:Tamoxifen; D000080924:Aldehyde Dehydrogenase 1 Family; C510223:ALDH1A1 protein, human; D050697:Retinal Dehydrogenase